New Alzheimer’s Imaging Test Provides NO Benefits, Only Profits for Drug Companies
by Vera Sharav
Alliance for Human Research Protection
On Friday, April 6, the FDA approved another of Eli Lilly’s “breakthroughs” whose clinical value is questionable (at best). The focus, in this instance, is not a therapeutic intervention, but rather a test using a radioactive imaging agent– a dye, brand name, Amyvid (florbetapir)–which is to be used in […]